|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
EBSCO_ocn835597378 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
130404s2012 nyu ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e pn
|c N$T
|d YDXCP
|d OCLCF
|d EBLCP
|d OCLCQ
|d VTS
|d AU@
|d STF
|d OCLCQ
|d K6U
|d OCLCQ
|d OCLCO
|d OCLCQ
|
| 020 |
|
|
|a 9781622571666
|q (electronic bk.)
|
| 020 |
|
|
|a 1622571665
|q (electronic bk.)
|
| 029 |
1 |
|
|a DEBBG
|b BV041049766
|
| 029 |
1 |
|
|a DEBBG
|b BV043775644
|
| 029 |
1 |
|
|a DEBSZ
|b 472781294
|
| 035 |
|
|
|a (OCoLC)835597378
|
| 050 |
|
4 |
|a RC267
|b .H67 2012eb
|
| 072 |
|
7 |
|a HEA
|x 039030
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.994
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Horizons in cancer research.
|n Volume 50 /
|c Hiroto S. Watanabe, editor.
|
| 260 |
|
|
|a New York :
|b Nova Science Publishers, Inc.,
|c 2012.
|
| 300 |
|
|
|a 1 online resource (xii, 164 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Horizons in cancer research ;
|v v. 50
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Online resource; title from pdf information screen (Ebsco, viewed April 4, 2013).
|
| 505 |
0 |
|
|a HORIZONS IN CANCER RESEARCH: VOLUME 50; HORIZONS IN CANCER RESEARCH: VOLUME 50; LIBRARY OF CONGRESS CATALOGING-IN-PUBLICATION DATA; CONTENTS; PREFACE; Chapter 1: GALLBLADDER CANCER: ETIOLOGY, PATHOGENESIS AND TREATMENT; INTRODUCTION; Epidemiology; Pathogenesis, Etiology and Risk Factors; MANAGEMENT; GALLBLADDER CANCER SUSPECTEDPRE-OPERATIVELY; ADDITIONAL SURGICAL CONSIDERATIONS; Diagnostic Laparoscopy; Lymph Node Dissection; Bile Duct Resection; UNSUSPECTED GALLBALDDER CANCER DISCOVERED INTRAOPERATIVELY; INCIDENTAL GALLBLADDER CARCINOMA FOUND POST-OPERATIVELY ON HISTOLOGICAL SECTIONING.
|
| 505 |
8 |
|
|a ADVANCED UNRESECTABLE GALLBLADDER CARCINOMACONCLUSION; REFERENCES; Chapter 2: AN OVERVIEW OF DOCETAXEL APPLICATIONS AND EFFECTS; ABSTRACT; INTRODUCTION; 1. Historic Overview; 2. Chemical Composition and Mechanisms of Action; 2.1. Chemical Composition; 2.2. Mechanisms of Action; 3. Therapeutic Applications and Benefits; 4. Benefits of Docetaxel Association with OtherAnticancer Drugs; Hormonal Modulators; Other Steroids; Immunotherapy; Antiangiogenic agents; DNA interference molecules; Microtubule Network Disrupters; 5. Adverse Side Effects; 6. Development of Resistance to Docetaxel.
|
| 505 |
8 |
|
|a 7. Future DirectionsCONCLUSION; REFERENCES; Chapter 3: METASTATIC CANCER PAIN MANAGEMENT TO THE BONE, SPINE AND LIVER: CURRENT ISSUES, INNOVATIVE TREATMENTS AND FUTURE DIRECTIONS; ABSTRACT; INTRODUCTION; PREVALENCE AND CAUSES OF PAININ ADVANCED CANCER; MEASURING PAIN INTENSITY; PRINCIPLES OF EFFECTIVE PAIN CONTROL; UNDER-MEDICATION OF PAINFUL BONE METASTASES; A MEASUREMENT TOOL: THE PAIN MANAGEMENT INDEX; Barriers of the Pain Management Index; INNOVATIONS IN RADIATION MANAGEMENTOF CANCER RELATED PAIN; Innovations in Radiotherapy for Bone and Spine Pain; Palliative Radiotherapy for Liver Pain.
|
| 505 |
8 |
|
|a FUTURE DIRECTIONSCONCLUSION; REFERENCES; Chapter 4: DOCETAXEL IN THE MANAGEMENT OF PATIENTS WITH HEAD AND NECK SQUAMOUS CELL CARCINOMA; ABSTRACT; 1. INTRODUCTION; 2. MAIN MECHANISMS OF TAXANE ACTION; 3. SAFETY PROFILE; 4. DOCETAXEL MONOTHERAPY; 5. INDUCTION CHEMOTHERAPY; 6. CONCOMITANT CHEMORADIOTHERAPY; 7. INTRA-ARTERIAL CHEMORADIOTHERAPY; 8. SECOND-LINE CHEMOTHERAPY IN RECURRENTOR METASTATIC DISEASE; 9. TREATMENT FOR LUNG METASTASIS FROM HNSCC:A PRELIMINARY STUDY OF DOCETAXELAND NEDAPLATIN [35]; 9.1. Patients and Methods; 9.2. Results; Patient Characteristics; Treatment for Lung Metastasis.
|
| 505 |
8 |
|
|a Survival Associated with Lung MetastasisTreatment Efficacy and Toxicity of Docetaxel-Based Chemotherapy; 10. FUTURE DIRECTIONS FOR MOLECULAR TARGETINGTHERAPIES; CONCLUSION; REFERENCES; Chapter 5: THE EFFECTS OF CYTOSKELETAL STRUCTURE CHANGES INDUCED BY DOCETAXEL ON GENE EXPRESSIONS: A VIEW FROM DIFFERENT POINTS OF DOCETAXEL FUNCTIONS; ABSTRACT; INTRODUCTION; DOCETAXEL AS AN ANTICANCER CHEMOTHERAPY DRUG; HEPATOCYTE FOR THE TOXICITY TESTING OF DRUG CANDIDATE CHEMICALS; THREE-DIMENSIONAL CULTURE OF HEPG2 CELLS; CHANGES OF DRUG METABOLISM-RELATING GENEEXPRESSIONS IN THREE-DIMENSIONAL CULTURE.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Cancer
|x Research.
|
| 650 |
|
6 |
|a Cancer
|x Recherche.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x Cancer.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Oncology.
|2 bisacsh
|
| 650 |
|
7 |
|a Cancer
|x Research.
|2 fast
|0 (OCoLC)fst00845497
|
| 700 |
1 |
|
|a Watanabe, Hiroto S.
|
| 830 |
|
0 |
|a Horizons in cancer research ;
|v v. 50.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=541948
|z Texto completo
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3021476
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 541948
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 10311738
|
| 994 |
|
|
|a 92
|b IZTAP
|
